Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Pfizer has dosed the first patient in a trial of a muscular dystrophy gene therapy, acquired as part of its $700 million takeover of Bamboo in 2016.
The first trial of Translate Bio's nebulized messenger RNA therapy is now due to start in mid-2018, with results due a year later.
The FDA lifted a clinical hold it placed on Bellicum's lead cell therapy, BPX-501, in January.
CymaBay's liver med seladelpar had "potent and sustained" efficacy in patients with primary biliary cholangitis.
The seroclearance gives a boost to Arrowhead as it plots a path back from safety concerns that derailed ARC-520 in 2016.
The biotech painted data from the trial as positive, but the outside world took a different view, sending Selecta’s stock down by more than 20%.
The FDA will make its decision on AbbVie's elagolix to Q3, as it needs more time to review liver function tests.
The Swedish biotech picked up small molecule multi-kinase inhibitor dovitinib in a belief its drug response predictor will up the chance of success.
Therapix Biosciences' THX-110 reduced Tourette symptoms in adults who had failed other treatments.
Antibiotics dubbed odilorhabdins (ODLs), inspired by soil-dwelling nematodes, hold promise for treating antibiotic-resistant infections.